AN2 Therapeutics (NASDAQ: ANTX) officer covers RSU taxes via sales

Rhea-AI Filing Summary

AN2 Therapeutics Chief Development Officer Sanjay Chanda reported two sales of AN2 Therapeutics common stock. On January 5, 2026, he sold 3,295 shares at $1.003 per share, and on January 6, 2026, he sold 5,956 shares at $1.012 per share. A footnote states these shares were sold under the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026, rather than as discretionary open‑market sales.

After these transactions, Chanda beneficially owned 75,823 shares of common stock directly. This amount includes 27,500 RSUs that vest annually in four equal parts from January 1, 2024, and 50,250 RSUs that vest annually in four equal parts from January 1, 2025, in each case subject to his continued service. The total also reflects a prior purchase of 5,000 shares under the company’s Employee Stock Purchase Plan on September 30, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chanda Sanjay

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S		3,295(1)	D	$1.003	81,779(2)(3)	D
Common Stock	01/06/2026		S		5,956(1)	D	$1.012	75,823(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.

2. Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 50,250 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025.

	/s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did AN2 Therapeutics (ANTX) report for Sanjay Chanda?

The filing reports that Chief Development Officer Sanjay Chanda sold shares of AN2 Therapeutics common stock on January 5 and 6, 2026 and disclosed his updated holdings.

How many ANTX shares did Sanjay Chanda sell and at what prices?

Chanda sold 3,295 shares on January 5, 2026 at $1.003 per share and 5,956 shares on January 6, 2026 at $1.012 per share.

Why were the AN2 Therapeutics shares sold in this Form 4?

A footnote explains the transactions represent shares sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026.

How many ANTX shares does Sanjay Chanda beneficially own after these sales?

Following the reported transactions, Chanda beneficially owned 75,823 shares of AN2 Therapeutics common stock directly.

What RSU awards for AN2 Therapeutics stock does Sanjay Chanda hold?

The disclosure notes that his holdings include 27,500 RSUs vesting in four annual installments from January 1, 2024 and 50,250 RSUs vesting in four annual installments from January 1, 2025, subject to continued service.

Does the Form 4 mention any shares acquired through an employee stock purchase plan?

Yes. A footnote states the adjusted total reflects the purchase of 5,000 shares under the issuer's Employee Stock Purchase Plan on September 30, 2025.